<DOC>
	<DOCNO>NCT01358721</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamic biologic property BMS-936558 subject metastatic renal cell carcinoma .</brief_summary>
	<brief_title>Phase I Biomarker Study ( BMS-936558 )</brief_title>
	<detailed_description>Intervention Model : Parallel Dose Comparison</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Women men â‰¥ 18 year age . Histologic confirmation renal cell carcinoma clear cell component . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) . Tumor site access repeat biopsy acceptable clinical risk . Previously treated subject must fail least 1 prior antiangiogenic agent maximum 3 prior systemic treatment renal cell cancer . Subjects treatment naive arm receive prior systemic therapy renal cell carcinoma . Active progress brain metastasis . Active concomitant . Active history autoimmune disease . Active use systemic corticosteroid . Prior therapy Cytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) , anti Programmed death1 ( antiPD1 ) , anti Programmed death ligand 1 ( antiPDL1 ) , anti Programmed death ligand 2 ( antiPDL2 ) , antiCD137 , antiCD40 , antiOX40 antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>